Erlotinib in advanced non-small-cell lung cancer after gefitinib failure

[引用][C] LONDON CANCER NEWS DRUGS GROUP Erlotinib re-challenge for the third or fourth-line treatment of NSCLC London and South East Regional Medicines …

II Phase, BC Cho
相关文章